2 results match your criteria: "Helmholtz Munich - German Research Center for Environmental Health (GmbH)[Affiliation]"

The state-of-the-art machine learning model for plasma protein binding prediction: Computational modeling with OCHEM and experimental validation.

Eur J Pharm Sci

January 2025

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. Electronic address:

Plasma protein binding (PPB) is closely related to pharmacokinetics, pharmacodynamics and drug toxicity. Existing models for predicting PPB often suffer from low prediction accuracy and poor interpretability, especially for high PPB compounds, and are most often not experimentally validated. Here, we carried out a strict data curation protocol, and applied consensus modeling to obtain a model with a coefficient of determination of 0.

View Article and Find Full Text PDF

Therapeutic Potential of Targeting Prokineticin Receptors in Diseases.

Pharmacol Rev

November 2023

Regenerative Nanomedicine (UMR 1260), INSERM, University of Strasbourg, Center of Research in Biomedicine of Strasbourg, Strasbourg, France (M.V., A.K., A.J., L.D., C.G.N.); Department of Physiology and Pharmacology (M.V., R.L.), and Department of Biochemical Sciences "Alessandro Rossi Fanelli" (R.M.), Sapienza University of Rome, Rome, Italy; University Grenoble Alpes, INSERM, CEA, Grenoble, France (M.B., N.A.); Unité de Biologie Fonctionnelle et Adaptative, Université Paris Cité, CNRS, Paris, France (S.M.); Department of Physiology and Pharamacology, Center for Neurologic Disease Research, University of Georgia, Athens, Georgia (A.G.K.); Department of Biochemistry, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil (M.A.P.); Moores Cancer Center, University of California, San Diego, La Jolla, California (N.F.); and Institute of Structural Biology, Helmholtz Munich - German Research Center for Environmental Health (GmbH), Neuherberg, Germany (I.V.T.); and BIGCHEM GmbH, Valerystr. 49, Unterschleissheim, Germany (I.V.T.)

Article Synopsis
  • Prokineticins (PKs) are small peptides discovered two decades ago, now recognized for their various roles as angiogenic, anorectic, proinflammatory agents, and their involvement in different diseases, making them potential biomarkers.
  • PKs interact with two receptors, PKR1 and PKR2, which have unique therapeutic potentials in treating conditions like cardiovascular, metabolic, neural diseases, pain, and cancer.
  • The article reviews the functions of the PK family, highlights knowledge gaps about their receptors and ligands, and suggests that understanding these proteins better could lead to new, safe treatment strategies.
View Article and Find Full Text PDF